585 related articles for article (PubMed ID: 33407585)
21. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.
Shi R; Zhao H; Zhao S; Yuan H
Aging (Albany NY); 2022 Jun; 14(12):5271-5291. PubMed ID: 35771147
[TBL] [Abstract][Full Text] [Related]
22. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
[TBL] [Abstract][Full Text] [Related]
23. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.
Lin P; Gao RZ; Wen R; He Y; Yang H
Front Immunol; 2021; 12():715460. PubMed ID: 34456923
[TBL] [Abstract][Full Text] [Related]
24. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.
Song F; Wang CG; Mao JZ; Wang TL; Liang XL; Hu CW; Zhang Y; Han L; Chen Z
Front Immunol; 2023; 14():1197152. PubMed ID: 37398672
[TBL] [Abstract][Full Text] [Related]
25. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
26. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
27. The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma.
Liu Z; Wang L; Liu L; Lu T; Jiao D; Sun Y; Han X
Front Oncol; 2021; 11():619242. PubMed ID: 33738257
[TBL] [Abstract][Full Text] [Related]
28. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
[TBL] [Abstract][Full Text] [Related]
29. Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q; Chen S; Hu Y; Huang W
Front Immunol; 2021; 12():711433. PubMed ID: 34512634
[TBL] [Abstract][Full Text] [Related]
30. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
[TBL] [Abstract][Full Text] [Related]
31. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches.
Kabashima A; Shimada S; Shimokawa M; Akiyama Y; Tanabe M; Tanaka S
J Hepatobiliary Pancreat Sci; 2021 Jan; 28(1):62-75. PubMed ID: 33259135
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
33. Clinical and genomic landscape of hepatocellular carcinoma subtypes with various proportions of nonleukocyte stromal cells.
Peng J; Li C; Zhou J; Peng J; Wang C; Lai S; Guo S; Zhong Y; Deng L; Tang X
Gene; 2020 Nov; 761():145028. PubMed ID: 32763490
[TBL] [Abstract][Full Text] [Related]
34. Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma.
Cai J; Wu S; Zhang F; Dai Z
Front Immunol; 2022; 13():952413. PubMed ID: 35911718
[TBL] [Abstract][Full Text] [Related]
35. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
36. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
37. Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma.
Huo J; Wu L; Zang Y
Med Sci Monit; 2020 Sep; 26():e925494. PubMed ID: 32945289
[TBL] [Abstract][Full Text] [Related]
38. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
39. Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma.
Hu B; Gao J; Shi J; Zhang F; Shi C; Wen P; Wang Z; Guo W; Zhang S
Front Immunol; 2022; 13():970117. PubMed ID: 35967375
[TBL] [Abstract][Full Text] [Related]
40. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions.
Zheng Q; Yang Q; Zhou J; Gu X; Zhou H; Dong X; Zhu H; Chen Z
Cancer Cell Int; 2021 Jun; 21(1):330. PubMed ID: 34193146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
